Lazard Asset Management
LKFT

Lazard Asset Management’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Lazard Asset Management’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-5
Closed – – 2333
2024
Q2 		$0 Sell
5
-117
-96% -$3.32K ﹤0.01% 2311
2024
Q1 		$3K Sell
122
-51
-29% -$1.9K ﹤0.01% 1919
2023
Q4 		$6K Buy
+173
New +$6.37K ﹤0.01% 2113

Other funds holding LKFT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
SBH
Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Lazard Asset Management's LKFT Position: Q3 2024 in Review

Lazard Asset Management sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q3 2024, closing a stake of 5 shares.

Lazard Asset Management first reported a position in LKFT in Q4 2023 and held it in 3 quarters. The position peaked at $6K in Q4 2023. 79 funds tracked by Wall St. Rank hold LKFT as of Q3 2024.

  • Lazard Asset Management reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q3 2024 after selling out during the quarter.
  • Lazard Asset Management sold 5 Lakefront Biotherapeutics American Depositary Shares shares in Q3 2024.
  • Lazard Asset Management first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q4 2023 and held it in 3 quarters.
  • Lazard Asset Management's Lakefront Biotherapeutics American Depositary Shares position peaked at $6K in Q4 2023.
  • 79 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q3 2024.

Based on Lazard Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.